- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cutaneous T-cell lymphoma (CTCL)
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 September 2025 PBAC Meetings - (PDF 907KB)
- Public Summary Document (PSD) March 2025 September 2025 PBAC Meetings - (Word 402KB)
Mogamulizumab – March 2025
Mogamulizumab; Solution concentrate for I.V. infusion 20 mg in 5 mL; Poteligeo® – March 2025 – September 2025
Last updated
12 March 2025